Howard Pien, Steven Owings, Gene Myers, Tim Germann, Bruce Mcreedy, Dan Stevens, David Deems, Michael Pellini, John Bishop | GenomeWeb
ImmunoGen announced last week the addition of Howard Pien to the company’s board of directors. Pien was formerly the chairman and CEO of Chiron from 2003 to 2006, and led the company through its acquisition by Novartis last year. Prior to joining Chiron, Pien held positions at SmithKline Beecham and its successor, GlaxoSmithKline.


Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.